Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Illumina enters into collaboration with Cancer Research UK
From the work, it is hoped that it will be possible in the future to design and validate biomarkers associated with prostate cancer susceptibility and disease progression, as
From the work, it is hoped that it will be possible in the future to design and validate biomarkers associated with prostate cancer susceptibility and disease progression, as
Indaflex is currently in phase II clinical development in Canada for the treatment of osteoarthritis. The cream makes use of AlphaRx’ formulation technology to deliver the active ingredient,
The collaboration will leverage proprietary technology from both organizations to identify favorable targets amenable to drug discovery. Under the five-year research agreement, Myriad will use its genetics, RNA
Many viruses, such as influenza, are surrounded by a single lipid membrane, or envelope, and to enter cells this membrane must be removed. Previously, all enveloped viruses were
The clinical trial, which is being undertaken at Maisonneuve-Rosemont Hospital in Montreal, will consist of 30 patients in two cohorts. Each cohort will receive PBI-1402 or placebo for
The study, published in the Journal of Consumer Research, shows that consumers exposed to marketing for remedies – including smoking cessation and debt consolidation programs – are more
Under the terms of the agreement, Miraculins will combine its internal research expertise with the research capabilities and patient network of Duke University Medical Center (DUMC). The collaboration
The new data provides additional insight into the drug’s mechanism of action, which is believed to inhibit tumor growth, bone metastases and angiogenesis. Results indicate that Abegrin’s mechanism
In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-142886, for co-development and commercialization with AstraZeneca. MEK is a critical enzyme
After the companies complete feasibility studies, InNexus will have a right to license one of Affimed’s antibodies, while Affimed will have the right to license the SuperAntibody technology